Member Info for Seawitch65

So.Looking at this interview we can expect assay results around w/ c 22nd June.

Still,good to know they arent sitting about on their hands and are taking opportunities as they see them.Assays res ults must be heading our way this week/ next week.We know they were dribbling in at PBs last interview with Stockbox on the 19th May ( 3 weeks ago).

Over 800 again! It' s been a while.The immediate news can, surely, only increase the SP.worth the wait and finally green again!😁

No idea.Perhaps inge108 might enlighten?.

As far as i know, there is no official confirmation that any major trial milestone has been met or "passed" yet. We're all just waiting on the upcoming EHA presentation and the summer readout.

The data being presented on Saturday, 13 June 2026 is not the clinical trial data from their current human patients; as you mentioned, that highly anticipated interim data from the TOPICAL trial is still on track for later this summer.

​Instead, Poolbeg Pharma (POLB) is presenting a scientific poster at the European Hematology Association (EHA) 2026 Congress in Stockholm.

​The presentation will showcase supporting pre-clinical data (laboratory and animal models) for their lead asset, POLB 001. Here is exactly what that data covers:

​In Vivo (Animal) Models: Data demonstrating POLB 001's ability to significantly reduce multiple key cytokines (like TNF, IFNγ, and IL-6) which are the main culprits behind dangerous Cytokine Release Syndrome (CRS).

​In Vitro (Lab/Cell) Data: Crucial evidence showing that while POLB 001 dampens these dangerous inflammatory cytokines, it does not impair the cancer-killing effectiveness of bispecific antibodies (the immunotherapy treatment).

​Why this matters right now

​Essentially, this EHA data acts as the scientific validation and "proof of concept" behind why they are running the current trial. It proves that the drug can stop the life-threatening side effects of cancer immunotherapies without accidentally stopping the cancer treatment itself from working.

​It lays the groundwork for the TOPICAL Phase 1b/2a trial in multiple myeloma patients, for which the interim data readout is still very much the major "summer catalyst" investors are waiting for.

Just to add that if we dont get the assay results ahead of the MRE I personally may start getting a little nervous.I also expect a delay on the MRE As i think end of June is optimistic but fingers crossed.

I think optioni B. The assay results wont be drip fed but will be shared ahead of the MRE.This will hopefully whet the appetites of institutiins and Alphamin!!!

I discovered that institutions are not able to invest in speculative mining stocks before a certain point which explains the lack of any real movement of the SP atm.

See below if youre interested...

Why Big Institutions Are Waiting for the MRE

​It can be puzzling to hear that major institutional funds haven't bought in yet, but this is completely standard for junior mining stocks. Large institutional funds have strict compliance mandates and investment committees. They legally or structurally cannot buy into a company based on speculative drilling "potential" alone—they require defined assets.

​They are waiting on the upcoming MRE (Mineral Resource Estimate) for a few critical reasons:

​The "JORC" Checklist: Institutions require a formal, independently verified resource statement (like a JORC or NI 43-101 compliant MRE) to prove there is commercially viable tin or copper in the ground.

​De-Risking: Until the MRE is published, the project is technically still classified as high-risk exploration. The MRE translates raw drill assays into an official number of tons and grades, effectively de-risking the asset.

​Valuation Models: Funds use mathematical formulas based on the total resource size to determine a fair value for the company. They literally cannot build their investment case until management delivers those definitive resource numbers.

​The Takeaway

​The sideways price action right now is just retail investors passing shares back and forth around the recent fundraise baseline. The real catalyst for a major re-rating isn't a lack of interest—it is a structural waiting game. Once the MRE drops and puts concrete data on the table, it opens the door for institutional money and larger strategic partners (like Alphamin) to officially enter the frame.

Ditto Mattpr1.

Though i am over 100 points off my average.Agree with your sentiment now though wouldnt have last year.

This is classic AIM. Tell investors that the FAT3 sign off is on target for the end of April.Dont tell them that the sign off is now due the end of May.Protect the SP.Obviously dont tell them that any positive sign off results will be tempered by a fund raise.Protect the Sp.

Oh dear...no sign off,no finance,no good news at all for investors. I hope ,for investors sake,the company can keep going and create profit opportunities,but they wont be getting further support from me.

VGLA.

Fwiw I dont think there was a leak.SP wouldve dropped like a stone if there had been.EIS stops the larger investors from selling off..Seems that the daily trading is very much retail investors.There were clues however i.e. no news for a full 4 weeks after the proposed timeline for the fat3 results.

...which is exactly what the market would have done,long before retail investors could log in.Potentially there is a problem with the EIS individuals though because the tax breaks might suggest liquidation is the preferred outcome.This rather than a slow death.BUT,lets hope they find the necessary finance to get back on track.Interesting that a fund raise WAS happening( im not thrilled to be proved right).What a blo##y disaster.Agree that suspension was the only thing they could do.I hope we are kept utd with developments in a timely fashion.

I wonder if theyll snnounce a raise on the coat tails of the FAT3 sign off.Hope not,but its possible?

Can only assume anticipation of the Fat 3 sign off( at last) as we enter the final week of May next week.Plus recent MM shenanigans?

Rome Resources CEO Paul Barrett speaks with StockBox about the company’s latest exploration progress across its tin and copper projects in the DRC, including the launch of a 600km airborne geophysics survey aimed at unlocking district-scale upside across the licence area.

The interview also covers the upcoming Kalayi resource estimate, ongoing drilling and assay work at Kalayi and Mont Agoma, and the growing strategic interest surrounding the company’s assets and future development pathways.

Likely cause issues with supply chain speeds.

Ok Andypaps.Yes.MRE is imminent and i agree with your perspective.I remain invested,accounting for the fact that im not panicking!🙄

Ok Andypaps.Yes.MRE is imminent and i agree with your perspective.I remain invested,accounting for the fact that im not panicking!🙄

How rude you are.Did i say anything to suggest i was 'panicking'.No.i did not.

The primary hotspot is in Ituri Province but there are suspected cases in neighbouring North Kivu Province.

The Bisie North Tin Project is located in the Walikale District of the North Kivu Province.Given that the WHO have explicitly flagged "mining-related mobility" as a massive risk factor for spreading this specific outbreak it sounds to me that there is a very real risk to RMR,no?